(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 January 2023 (12.01.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/283610 A1

(51) International Patent Classification:
C07D 401/14 (2006.01) *A61K 31/5025* (2006.01)
C07D 487/04 (2006.01) *A61K 31/519* (2006.01)
C07D 519/00 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2022/073522

(22) International Filing Date:
07 July 2022 (07.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/219,160 07 July 2021 (07.07.2021) US
63/354,017 21 June 2022 (21.06.2022) US

(71) Applicants: **BIOGEN MA INC.** [US/US]; 225 Binney Street, Cambridge, MA 02142 (US). **C4 THERAPEUTICS, INC.** [US/US]; 490 Arsenal Way, Suite #200, Watertown, MA 02472 (US).

(72) Inventors: **GUCKIAN, Kevin, M.**; c/o Biogen Ma Inc., 225 Binney Street, Cambridge, MA 02142 (US). **PETERSON, Emily, Anne**; c/o Biogen Ma Inc, 225 Binney Street, Cambridge, MA 02142 (US). **GAO, Fang**; c/o Biogen Ma Inc, 225 Binney Street, Cambridge, MA 02142 (US). **EVANS, Ryan**; c/o Biogen Ma Inc, 225 Binney Street, Cambridge, MA 02142 (US). **STEFAN, Eric**; c/o Biogen Ma Inc, 225 Binney Street, Cambridge, MA 02142 (US). **YAP, Jeremy, L.**; 8 Pinewood Ave., Sudbury, MA 01776 (US). **ANDERSON, Corey, Don**; 24 N Crescent Circuit, Brighton, MA 02135 (US). **O'SHEA, Morgan, Welzel**; 91 Brewster Road, Waltham, MA 02451 (US). **AHN, Jae, Young**; 12 Bay State Ave., #2, Somerville, MA 02144 (US). **NASVESCHUK, Christopher, G.**; 15 Philips Road, Stoneham, MA 02180 (US). **HENDERSON, James, A.**; 41 Trailside Road, Weston, MA 02493 (US).

(74) Agent: **ZHANG, Xin** et al.; Mccarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS



(I)

(57) Abstract: This disclosure relates to compounds of Formula (A): IRAK—L—DSM (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches IRAK to DSM; and IRAK is an IRAK4 binding moiety represented by Formula (I) that is covalently attached to linker L; in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of IRAK4 proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of IRAK4 proteins. The present disclosure also provides methods of treating disorders responsive to modulation of IRAK4 activity and/or degradation of IRAK4 with at least one compound described herein.

WO 2023/283610 A1